Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma

Neuro-Oncology

Volumn 8, Issue 3, 2006, Pages 253-260

  Brandes, Alba A ^a,b   Nicolardi, Linda ^a   Tosoni, Alicia ^a   Gardiman, Marina ^b   Iuzzolino, Paolo ^c   Ghimenton, Claudio ^d   Reni, Michele ^e   Rotilio, Antonino ^b   Sotti, Guido ^a   Ermani, Mario ^b  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c SAN MARTINO HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Adjuvant chemotherapy; Anaplastic astrocytoma; Clinical trials; PCV; Temozolomide

Indexed keywords

LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG DERIVATIVE; PCV PROTOCOL; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLIOBLASTOMA; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SKIN ALLERGY; THROMBOCYTOPENIA; ADOLESCENT; ASTROCYTOMA; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADJUVANTS, PHARMACEUTIC; ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; DACARBAZINE; FEMALE; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; PROCARBAZINE; RETROSPECTIVE STUDIES; SURVIVAL RATE; VINCRISTINE;

EID: 34047202235     PISSN: 15228517     EISSN: None     Source Type: Journal    
DOI: 10.1215/15228517-2006-005     Document Type: Article

References (24)

1. Buckner, J.C. (2003) Factors influencing survival in high-grade gliomas. Semin. Oncol. 30, 10-14.
2. CBTRUS, Central Brain Tumor Registry of the United States (2004) Primary Brain Tumors in the United States: Statistical Report, 1997-2001. Available at http://www.cbtrus.org/2004-2005/2004-2005.html.
3. Cohen, Z.R., Suki, D., Shi, W., Weinberg, J.S., DeMonte, F., McCutcheon, I.E., Hassenbusch, S.J., Gokaslan, Z.L., Rhines, L.D., Sawaya, R., and Lang, F.F. (2002) Surgical resection of anaplastic astrocytoma: Prognostic factors and outcome. Neuro-Oncology 4, 367 (abstract 216).
4. Cox, D. (1972) Regression models and life-tables. J. R. Stat. Soc. B 34, 187-220.
5. Curran, W.J., Jr., Scott, C.B., Norton, J., Nelson, J.S., Weinstein, A.S., Fischbach, A.J., Chang, C.H., Rotman, M., Asbell, S.O., Krisch, R.E., and Nelson, D.F. (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst. 85, 704-710.
6. Dinnes, J., Cave, C., Huang, S., and Milne, R. (2002) A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer 86, 501-505.
7. Donahue, B., Scott, C.B., Nelson, J.S., Rotman, M., Murray, K.J., Nelson, D.F., Banker, F.L., Earle, J.D., Fischbach, J.A., Asbell, S.O., Caspar, L.E., Markoe, A.M., and Curran, W. (1997) Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: A report of Radiation Therapy Oncology Group 83-02. Int. J. Radiat. Oncol. Biol. Phys. 38, 911-914.
8. Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M., and Canellos, G.P. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597.
9. Kaplan, E., and Meier, P. (1958) Nonparametric estimation for incomplete observations. J. Am. Stat. Assoc. 53, 457-481.
10. Kleihues, P., Louis, D.N., Scheithauer, B.W., Rorke, L.B., Reifenberger, G., Burger, P.C., and Cavenee, W.K. (2002) The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol. 61, 215-225.
11. Laws, E.R., Parney, I.F., Huang, W., Anderson, F., Morris, A.M., Asher, A., Lillehei, K.O., Bernstein, M., Brem, H., Sloan, A., Berger, M.S., and Chang, S. (2003) Survival following surgery and prognostic factors for recently diagnosed malignant glioma: Data from the Glioma Outcomes Project. J. Neurosurg. 99, 467-473.
12. Levin, V.A., Silver, P., Hannigan, J., Wara, W.M., Gutin, P.H., Davis, R.L., and Wilson, C.B. (1990) Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18, 321-324.
13. Levin, V.A., Hess, K.R., Choucair, A., Flynn, P.J., Jaeckle, K.A., Kyritsis, A.P., Yung, W.K., Prados, M.D., Bruner, J.M., Ictech, S., Gleason, M.J., and Kim, H.W. (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin. Cancer Res. 9, 981-990.
14. Macdonald, D.R., Cascino, T.L., Schold, S.C., Jr., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280.
15. McDonald, J.M., See, S.J., Tremont, I.W., Colman, H., Gilbert, M.R., Groves, M., Burger, P.C., Louis, D.N., Giannini, C., Fuller, G., Passe, S., Blair, H., Jenkins, R.B., Yang, H., Ledoux, A., Aaron, J., Tipnis, U., Zhang, W., Hess, K., and Aldape, K. (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104, 1468-1477.
16. MRC, Medical Research Council (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J. Clin. Oncol. 19, 509-518.
17. Prados, M.D., Scott, C., Curran, W.J., Jr., Nelson, D.F., Leibel, S., and Kramer, S. (1999a) Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of Radiation Therapy Oncology Group protocols comparing survival with carmustine or PCV adjuvant chemotherapy. J. Clin. Oncol. 17, 3389-3395.
18. Prados, M.D., Scott, C., Sandler, H., Buckner, J.C., Phillips, T., Schultz, C., Urtasun, R., Davis, R., Gutin, P., Cascino, T.L., Greenberg, H.S., and Curran, W.J., Jr. (1999b) A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: A preliminary report of RTOG 9404. Int. J. Radiat. Oncol. Biol. Phys. 45, 1109-1115.
19. See, S.J., and Gilbert, M.R. (2004) Anaplastic astrocytoma: Diagnosis, prognosis, and management. Semin. Oncol. 31, 618-634.
20. Stewart, L.A. (2002) Chemotherapy in adult high-grade glioma: A systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359, 1011-1018.
21. Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., Curschmann, J., Janzer, R.C., Ludwin, S.K., Gorlia, T., Allgeier, A., Lacombe, D., Cairncross, J.G., Eisenhauer, E., and Mirimanoff, R.O. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987-996.
22. Tortosa, A., Vinolas, N., Villa, S., Verger, E., Gil, J.M., Brell, M., Caral, L., Pujol, T., Acebes, J.J., Ribalta, T., Ferrer, I., and Graus, F. (2003) Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 97, 1063-1071.
23. Yung, W.K., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, M.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., Friedman, A.M., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group (erratum in J. Clin. Oncol. [1999] 17, 3693).
24. J. Clin. Oncol. 17, 2762-2771.